351 related articles for article (PubMed ID: 18698221)
1. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
Nishiyama A; Nakagawa T; Kobori H; Nagai Y; Okada N; Konishi Y; Morikawa T; Okumura M; Meda I; Kiyomoto H; Hosomi N; Mori T; Ito S; Imanishi M
J Hypertens; 2008 Sep; 26(9):1849-59. PubMed ID: 18698221
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
Nishiyama A; Kobori H; Konishi Y; Morikawa T; Maeda I; Okumura M; Kishida M; Hamada M; Nagai Y; Nakagawa T; Ohashi N; Nakano D; Hitomi H; Imanishi M
J Pharmacol Exp Ther; 2010 Mar; 332(3):1072-80. PubMed ID: 19940106
[TBL] [Abstract][Full Text] [Related]
3. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Sofue T; Kiyomoto H; Kobori H; Urushihara M; Nishijima Y; Kaifu K; Hara T; Matsumoto S; Ichimura A; Ohsaki H; Hitomi H; Kawachi H; Hayden MR; Whaley-Connell A; Sowers JR; Ito S; Kohno M; Nishiyama A
Am J Hypertens; 2012 May; 25(5):604-11. PubMed ID: 22318512
[TBL] [Abstract][Full Text] [Related]
4. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.
Ihara G; Kiyomoto H; Kobori H; Nagai Y; Ohashi N; Hitomi H; Nakano D; Pelisch N; Hara T; Mori T; Ito S; Kohno M; Nishiyama A
J Hypertens; 2010 Nov; 28(11):2289-98. PubMed ID: 20706133
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
Zhang Z; Li Z; Cao K; Fang D; Wang F; Bi G; Yang J; He Y; Wu J; Wei Y; Song X
J Hypertens; 2017 Jul; 35(7):1442-1456. PubMed ID: 28244896
[TBL] [Abstract][Full Text] [Related]
7. Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats.
Fan YY; Kobori H; Nakano D; Hitomi H; Mori H; Masaki T; Sun YX; Zhi N; Zhang L; Huang W; Zhu B; Li P; Nishiyama A
Horm Metab Res; 2013 May; 45(5):338-43. PubMed ID: 23322513
[TBL] [Abstract][Full Text] [Related]
8. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats.
Kuno Y; Iyoda M; Shibata T; Hirai Y; Akizawa T
Br J Pharmacol; 2011 Mar; 162(6):1389-400. PubMed ID: 21133896
[TBL] [Abstract][Full Text] [Related]
9. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Zhao ZQ; Luo R; Li LY; Tian FS; Zheng XL; Xiong HL; Sun LT
Can J Diabetes; 2013 Jun; 37(3):156-68. PubMed ID: 24070838
[TBL] [Abstract][Full Text] [Related]
11. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S;
Hypertens Res; 2008 Apr; 31(4):657-64. PubMed ID: 18633177
[TBL] [Abstract][Full Text] [Related]
12. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Koga K; Yamagishi S; Takeuchi M; Inagaki Y; Amano S; Okamoto T; Saga T; Makita Z; Yoshizuka M
Mol Med; 2002 Oct; 8(10):591-9. PubMed ID: 12477969
[TBL] [Abstract][Full Text] [Related]
13. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Nagai Y; Yao L; Kobori H; Miyata K; Ozawa Y; Miyatake A; Yukimura T; Shokoji T; Kimura S; Kiyomoto H; Kohno M; Abe Y; Nishiyama A
J Am Soc Nephrol; 2005 Mar; 16(3):703-11. PubMed ID: 15647337
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.
Li C; Yang CW; Park CW; Ahn HJ; Kim WY; Yoon KH; Suh SH; Lim SW; Cha JH; Kim YS; Kim J; Chang YS; Bang BK
Kidney Int; 2003 Feb; 63(2):454-63. PubMed ID: 12631111
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
[TBL] [Abstract][Full Text] [Related]
16. Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats.
Taniguchi M; Kim S; Zhan Y; Iwao H
Hypertens Res; 2002 Mar; 25(2):287-94. PubMed ID: 12047045
[TBL] [Abstract][Full Text] [Related]
17. Abnormal renal structural alterations during the development of diabetes mellitus in Otsuka Long-Evans Tokushima Fatty rats.
Koike T; Tomoda F; Kinuno H; Inoue H; Takata M
Acta Physiol Scand; 2005 May; 184(1):73-81. PubMed ID: 15847646
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin blockade improves cardiac and renal complications of type II diabetic rats.
Kim S; Wanibuchi H; Hamaguchi A; Miura K; Yamanaka S; Iwao H
Hypertension; 1997 Nov; 30(5):1054-61. PubMed ID: 9369255
[TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
[TBL] [Abstract][Full Text] [Related]
20. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S
J Int Med Res; 2005; 33(6):677-86. PubMed ID: 16372586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
